Traders should anticipate near-term share price pressure due to dilution from the new issuance, especially given recent insider selling. Monitor for exercise of the underwriters' option, which would increase dilution. Use of proceeds may provide insight into pipeline development timelines.
Price Chart
Executive Summary
Apogee Therapeutics priced an underwritten public offering of 5,000,000 shares at $70.00 per share, raising approximately $350 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 750,000 shares. The offering is expected to close on March 26, 2026, subject to customary conditions.
Key Financial Metrics
Key Facts
- Apogee Therapeutics is offering 5,000,000 shares of common stock at $70.00 per share.
- Gross proceeds from the offering are expected to be approximately $350 million.
- Underwriters have a 30-day option to purchase up to an additional 750,000 shares.
- The offering is expected to close on March 26, 2026, subject to customary closing conditions.
- Jefferies, TD Cowen, Stifel, and Guggenheim Securities are joint book-running managers.
Financial Impact
$350 million in gross proceeds before expenses; potential for up to $402.5 million if underwriters exercise full option (750,000 additional shares at $70).
Risk Factors
- Significant equity dilution for existing shareholders.
- Potential downward pressure on stock price post-offering due to increased supply and recent insider selling.
- Forward-looking statements about clinical programs are speculative and subject to development risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261899 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access